Business Wire

Celltrion Healthcare: Biosimilars Have the Potential to Deliver Dramatic Cost Savings for US and European Healthcare Systems

Jaa

Celltrion Healthcare outlined their vision of ‘shaping future healthcare by improving access to biosimilars’ at the 5th Annual Biosimilars USA Conference in New Jersey, US.

Biosimilars offer healthcare providers and patients greater treatment choice and value, better access to treatments and improved patient outcomes. According to data provided by IMS Health, biosimilars could lead to cumulative savings of up to 107 billion USD by 2020 in the United States (US) and the top five European Union (EU) countries.1 The EU has made significant progress in unlocking the potential of biosimilars through continuous education of providers, payers and patients. This has been critical to EU biosimilar acceptance but has not been seen in the US, which has lagged behind.

During a presentation on the opportunities and challenges presented by the use of biosimilars in the US, Celltrion Healthcare highlighted several challenges affecting the uptake of biosimilars within the US market. Both physicians and patients in the US lack confidence in biosimilars due to a low level of education and awareness. According to a survey, 67% of patients said they were “unaware” of biosimilars and 70% selected “no” as a response to the statement “is a biosimilar is safe?”2,3 Compounding this lack of understanding are anti-biosimilar campaigns running in the US which are increasing the negative public perception of biosimilars. In addition, legal battles like patent litigation have restricted uptake of biosimilars and have hindered progress in the US.

The lower cost of biosimilars means that more patients can receive effective treatments without increasing healthcare budgets. Furthermore, treatment at a lower cost generates savings that can be put towards funding innovative treatments or combination treatments, ultimately benefitting more patients and on a longer-term basis.

“A key factor in overcoming barriers to US market entry is sharing the positive experiences of both healthcare professionals and patients. In particular, it is important to highlight best practice and work together to ensure as many patients as possible in the US have access to treatment through the use of high quality, more cost-effective biosimilars,” said Mr HoUng Kim, Head of Strategy and Operations Division, Celltrion Healthcare. “As innovators within the biosimilar field, we are looking forward to launching subcutaneous infliximab next year. We expect that this will generate further cost savings in addition to improved convenience as dual formulations would provide personalised therapeutic approaches to optimise patient outcomes.”

At the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2018 which took place last week in Barcelona, Spain, Celltrion Healthcare presented new financial forecast data, which showed European health services could save hundreds of millions of euros through the use of biosimilars. For example, predicted budgetary savings in the 28 countries of the European Union with trastuzumab biosimilar, range from €872 million to €2,635 million, which would allow up to an additional 134,000 patients to gain access to trastuzumab over a five-year period.4

Speaking at ISPOR, Professor Gulácsi, Head of Department of Health Economics, Corvinus University of Budapest, Hungary, discussed the long term benefits and cost-effectiveness of TNFi treatment, including biosimilar infliximab, in methotrexate-naïve patients with rheumatoid arthritis (RA), “Our systematic review and meta-analysis has demonstrated the long-term benefits of TNFi treatment versus other treatment strategies in methotrexate-naïve patients with RA. Results from our probabilistic Markov model demonstrated that biosimilar infliximab in early RA is cost effective in Denmark, Finland, Sweden, Norway, France, Germany, Italy, Spain, the United Kingdom and Hungary. Infliximab biosimilar intravenous is the most cost effective option at this time, and I believe that this advantage will be further strengthened by the introduction of subcutaneous formulation."

“Budget impact modelling is an important tool when assessing the financial impact of biosimilars,” said Aidan Byrne, Consultant, Health Economics and Outcome Research / Real-World Insights, IQVIA, United Kingdom. “Due to the significant cost-saving we have seen to date, the role that biosimilars play in improving the sustainability of healthcare systems is clear.”

--- Ends---

Notes to editors:

About rheumatoid arthritis
In Europe, more than 2.9 million people have rheumatoid arthritis (RA), many of whom are of working age. On average, every third person with RA becomes work disabled and up to 40 per cent leave work completely within 5 years of diagnosis.5 Although there is no cure for RA, there are many treatments that can reduce inflammation and ease pain. As with all rheumatic diseases early diagnosis and intervention is key.

About CT-P13 (biosimilar infliximab)
CT-P13 is developed and manufactured by Celltrion, Inc. and was the world’s first monoclonal antibody biosimilar approved by the European Commission (EC). It is indicated for the treatment of eight autoimmune diseases including rheumatoid arthritis and IBD. It was approved by the EC under the trade name Remsima® in September 2013 and launched in major EU countries in early 2015. The US FDA approved CT-P13 in April 2016 under the trade name Inflectra®. CT-P13 is approved in more than 88 countries (as of August 2018) including the US, Canada, Japan and throughout Europe.

About Celltrion Healthcare
Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavors to offer high-quality cost-effective solutions through an extensive global network that spans more than 120 different countries. For more information please visit: http://www.celltrionhealthcare.com/

References

1 Delivering on the potential of biosimilar medicines—The role of functioning competitive markets IMS institute for healthcare informatics; 2016
2 Cohen H, Beydoun D, Chien D, et al. Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians. Adv Ther. 2016;33(12):2160-2172.
3 Jacobs I, Singh E, Sewell KL, Al-sabbagh A, Shane LG. Patient attitudes and understanding about biosimilars: an international crosssectional survey. Patient Prefer Adherence. 2016;10:937-48
4 Suh D, Suh DC, Lee SM. PCN69: Budget Impact of Substituting Biosimilar Trastuzumab (CT-P6) In Treating Gastric Cancer and Breast Cancer in 28 European Countries. Poster presented at: ISPOR Europe 2018.
5 NRAS, European Fit for Work Report. Available at www.nras.org.uk/european-fit-for-work-report. [Accessed Aug, 2018].

Contact information

Emma Gorton
egorton@hanovercomms.com
+44 203 817 6791

Georgia Featherston
gfeatherston@hanovercomms.com
+44 203 817 6718

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

H.I.G. Europe to Acquire Polyurethane Systems Business from Covestro17.6.2019 11:05:00 EESTTiedote

H.I.G. Capital, LLC ("H.I.G."), a leading global private equity investment firm with over €26 billion of equity capital under management, is pleased to announce that an affiliate has signed a definitive agreement to acquire the European Polyurethane Systems Business (the “Company”) in a carve-out transaction from Covestro AG. The transaction is subject to clearing by the relevant antitrust authorities with closing anticipated for the second half of 2019. The European Polyurethane Systems Business operates four systems houses in Germany, Denmark, the Netherlands and Spain. It employs approximately 250 full-time employees and generates annual sales of approximately €230 million. Systems houses develop and formulate tailor-made ready-to-use chemical blends for the production of a wide range of polyurethane products such as insulation materials, foams, shoe soles, and building materials. The Company serves a wide range of small- and mid-sized customers across Europe and will be led by Dr.

Norsk Titanium Announces Larger Capacity Rapid Plasma Deposition™ (RPD™) Machine17.6.2019 11:00:00 EESTTiedote

Officials with Norsk Titanium (Norsk) announced today the company has designed and is currently building a larger-scale Rapid Plasma Deposition™ (RPD™) machine. This new machine enables manufacturing of larger, more complex aircraft and engine components, at faster print speeds. The new RPD™ machine, the G-IVL, will use the same advanced RPD™ technology of Norsk’s current additive manufacturing process. Norsk’s patented RPD™ technology and equipment utilizes proprietary process controls to melt titanium wire with plasma torches, in an argon environment to produce near-net shape components for airframe and aircraft engine applications. The Norsk G-IVL machine will expand the printing envelope to 190cm by 40cm by 60cm. It will print double-sided, as well as single-sided components, of complex geometries and deposit material in excess of 8kg per hour. The resultant component will have the material qualities equivalent to forgings. “The G-IVL machine will significantly expand Norsk’s capab

TYAN Powers AI and HPC with 2nd Gen Intel® Xeon® Scalable Processor-based Server Platforms at ISC 201917.6.2019 11:00:00 EESTTiedote

TYAN®, an industry-leading server platform design manufacturer and a MiTAC Computing Technology Corporation subsidiary, is showcasing its new 2nd gen Intel® Xeon® Scalable processor-based platforms that are optimized for predictive analytics, machine learning, and HPC applications at ISC 2019 from June 17-19 at Messe Frankfurt, booth C-1250. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190617005020/en/ TYAN's Thunder HX Lineup Designed for AI Optimization and HPC Revolution (Photo: Business Wire) “The most demanding workloads including HPC, AI deep learning, data analytics, and multi-cloud infrastructure require maximum performance across compute, memory, storage, and network resources, “said Danny Hsu, Vice President of MiTAC Computing Technology Corporation's TYAN Business Unit. “2nd gen Intel Xeon Scalable processors provide a powerful foundation for TYAN server platforms that enables us to deliver performance enhanceme

Appointment of Mark Wood as Chairman of HomeServe Labs17.6.2019 11:00:00 EESTTiedote

HomeServe plc (“HomeServe”, “the Group”), the international home repairs and improvements business, is pleased to announce the appointment of Mark Wood CBE as non-Executive Chairman of HomeServe Labs, the unit within HomeServe that developed LeakBot. HomeServe Labs is the innovation arm of HomeServe which in 2016 launched LeakBot, a patented smart leak alarm that can detect leaks anywhere on a mains water system. Water leaks are one of the major causes of claims on home insurance policies across Western Europe and the US, and LeakBot is designed specifically to help insurance companies prevent water leak claims by catching the leaks early. Craig Foster, LeakBot CEO, said: "Mark Wood is a previous CEO of AXA and a veteran of the insurance industry. This experience will really benefit us as a B2B Insuretech. Mark is also a successful entrepreneur himself, and more recently added a huge amount of value to promising fintech start-ups like PensionBee. With Mark on board as our new Chairman,

L&T Technology Services Successfully Concludes Its Engineering The Change Campaign in Europe with 24-Hour Hackathon17.6.2019 10:30:00 EESTTiedote

L&T Technology Services Limited (NSE: LTTS), a leading global pure-play engineering services company, successfully concluded its Engineering the Change campaign in Munich with a 24-hour hackathon. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190617005290/en/ Caption - Left to right: Nitin Ugale from Sulzer | Gaurav Gupta from LTTS | Winners - Annabel Michel; Lars Konig; Atenea Fernandez Rozaoilla; Luca Setili; Till Neumeier | David Humphrey from ARC Advisory Group | Samir Bagga from LTTS | Nawida Martinozzi from Nokia (Photo: Business Wire) The company’s 16-day pan Europe initiative included a 3,000 km innovation-on-wheels drive covering Greater Manchester & Ellesmere Port (Cheshire) in the UK, Amiens & Paris in France and Eindhoven in Netherlands, culminating in Germany. A total of 230 visitors, including customers, analysts, industry experts, government officials, local authorities and engineering students attended the d

Philip Morris International Holds ‘Open Mic’ at 2019 Cannes Lions Festival17.6.2019 10:00:00 EESTTiedote

Philip Morris International (PMI) (NYSE: PM) announced today its return to the Cannes Lions International Festival of Creativity to engage with those who are actively creating and shaping meaningful change in the world. Working from its central theme of “Open Mic,” PMI will foster conversations around unexpected and provocative ideas, concepts and views with some of today’s boldest thinkers at the gathering known for bringing together the world’s most creative people to discuss new ideas, pioneering research and emerging technologies that help make and shape popular culture. “For PMI, attending Cannes is a surprising juxtaposition of what people may expect of us. But that’s what we need to do as we strive to unsmoke the world: be bold, cut through the haze and have conversations about the future,” said Jacek Olczak, chief operating officer for PMI. Returning to Cannes for the second year in a row, PMI will host a series of panels, one-on-one conversations and events that focus on encou

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme